PerkinElmer acquires BioLegend for $5.25B

By The Science Advisory Board staff writers

September 20, 2021 -- PerkinElmer announced it has completed its $5.25 billion acquisition of life science antibody and reagent company BioLegend, a deal first announced in July.

The acquisition expands PerkinElmer's life science portfolio into cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.